加载中
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
收盘时
US$2.42
+US$0.01 · +0.41%
盘后
US$2.42
US$0.00 · 0.00%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
日内区间
当前US$2.42
52周区间
当前US$2.42
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
47
合理估值
情绪
50
多空交织
风险
41
风险偏高
动量
61
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
日内区间
当前US$2.42
52周区间
当前US$2.42
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 83万 USD | — | — | — | 5万 USD |
| 毛利 | −83万 USD | — | — | — | −5万 USD |
| 研究与开发 | 4826万 USD | 4379.5万 USD | 3211.5万 USD | 2586.2万 USD | 2811.9万 USD |
| 销售、一般及管理费用 | 1469万 USD | 1059.1万 USD | 481.9万 USD | 390.4万 USD | 1164.9万 USD |
| 营业费用 | 6212万 USD | 5438.6万 USD | 3693.4万 USD | 2976.6万 USD | 3976.8万 USD |
| 利息收入 | 344.1万 USD | 201.3万 USD | 162.3万 USD | 25.4万 USD | — |
| 利息支出 | — | 30万 USD | — | — | — |
| 折旧和摊销 | 83万 USD | 66.2万 USD | 56万 USD | 38.7万 USD | 5万 USD |
| 营业利润 | −6295万 USD | −5438.6万 USD | −3693.4万 USD | −2976.6万 USD | −3981.8万 USD |
| 净利润 | −5951.7万 USD | −5267.3万 USD | −3531.1万 USD | −2951.2万 USD | −3977万 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI418.93万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM139.01万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF110.98万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO54.77万0.00%180亿 USD0.06%US$112.27-0.35%
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMED22.46万0.68%3296.48万 USD0.44%US$33.6345-0.70%
iShares Micro-Cap ETFIWC19.99万0.02%13.17亿 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM13万0.11%1.17亿 USD0.73%US$15.8484-0.58%
Vanguard Russell 2000 Value ETFVTWV8.81万0.01%14亿 USD0.06%US$185.97+0.08%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMEDiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Value ETFVTWVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
